Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Zydus receives final approval from USFDA for Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg".
Press Release Apr 30 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Niacin Extended-Release Tablets in various strengths. These tablets are indicated for managing cholesterol levels and reducing the risk of myocardial infarction in certain patients. The manufacturing will take place at Zydus's facility in Moraiya, Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 26 2025
- Press Release Apr 25 2025
- ITC Reversal Of Common ITC U/s17(2) Required In Relation To Activity Of Subscription And Redemption Of Mutual Funds
- Press Release Apr 17 2025
- Press Release Apr 16 2025
Later from Zydus Lifesciences
- Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
- Press Release May 08 2025
- Press Release May 14 2025
- Press Release May 20 2025
- Press Release May 23 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences